Insys Therapeutics Announces Stock Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Subsys Pushes Insys Therapeutics (INSY) to 3Q Beat; Piper Jaffray Reiterates Overweight
November 6, 2015 9:57 AM ESTPiper Jaffray reiterated an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and raised the price target to $49.00 (from $48.00), following the company's 3Q15 earnings report. Insys reported 3Q15 EPS of $0.50, on revenues of $91M, well ahead of Street estimates. Subsys once again showed strong sequential growth, with sequential sales growth of 19% over 2Q15. Management suggested... More
Insys Therapeutics (INSY) CEO Babich Steps Down
November 5, 2015 6:59 AM ESTInsys Therapeutics, Inc. (NASDAQ: INSY) announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will continue to serve of the Chairman of the Companys Board of Directors. Daniel Brennan has been appointed Executive Vice President and Chief Operating Officer effective November 1, 2015.
It has been a privilege to lead Insys for the past six... More
Insys Therapeutics (INSY) Approves $50M Common Stock Buyback
November 5, 2015 6:53 AM ESTInsys Therapeutics (Nasdaq: INSY) announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we... More
